Government-Owned Inventions; Availability for Licensing, 57563-57565 [2014-22763]
Download as PDF
<![CDATA[
57563
Federal Register / Vol. 79, No. 186 / Thursday, September 25, 2014 / Notices
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
DATES: Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
Submit Comments and for Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Winnie Martinez,
Project Officer, 6707 Democracy Blvd.,
Bethesda, MD, 20892 or call non-tollfree number (301) 435–2988 or Email
your request, including your address to:
Winnie.Martinez@nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION:
Proposed Collection: Office of
Minority Health Research Coordination
post-doctoral educational level
individuals into OMHRC research
training and mentor programs: The
Short-Term Research Experience for
Underrepresented Persons (STEP–UP),
the Diversity Summer Research Training
Program (DSRTP) for Undergraduate
Students, the NIH/NMA Program on
Careers in Academic Medicine and the
Network of Minority Health Research
Investigators (NMRI). Identification of
participants to matriculate into the
program and initiatives comes from
applications and related forms hosted
through the NIDDK Web site. The
proposed information collection activity
is necessary in order to determine the
eligibility and quality of potential
awardees for traineeship in these
programs.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
3,989.
Training and Mentor Programs
Applications, 0925–NEW, Existing
collection in use without OMB control
number, National Institute of Diabetes
and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health
(NIH).
Need and Use of Information
Collection: In 2000, the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) of the
National Institutes of Health (NIH)
established the Office of Minority
Health Research Coordination (OMHRC)
to address the burden of diseases and
disorders that disproportionately impact
the health of minority populations. One
of the major goals of the office is to
build and sustain a pipeline of
researchers from underrepresented
populations in the biomedical,
behavioral, clinical, and social sciences,
with a focus on NIDDK mission areas.
The office accomplishes this goal by
administering a variety of programs and
initiatives to recruit high school through
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of form
Short-Term Research Experience for Underrepresented Persons (STEP–
UP) ...............................................................................................................
STEP–UP Mentor Training Form (SMTF) .......................................................
Reference Recommendation form STEP–UP, DSRTP ...................................
Survey—STEP–UP Feedback Form ...............................................................
Survey—Mentor Feedback Form .....................................................................
Diversity Summer Research Training Program (DSRTP) ...............................
Survey—DSRTP Feedback Form ....................................................................
Network of Minority Health Research Investigators (NMRI) Criteria Form .....
Survey—NMRI Feedback Form .......................................................................
Survey—NMRI Mentor Form ...........................................................................
NMRI Questionnaire ........................................................................................
NIH/NMA Fellows Program on Careers in Academic Medicine (NIH/NMA) ...
Survey—NIH/NMA Feedback Form .................................................................
Dated: September 5, 2014.
Frank Holloman,
NIDDK Project Clearance Liaison, Office of
Management Policy Analysis, National
Institute of Diabetes and Digestive and Kidney
Diseases, NIH.
[FR Doc. 2014–22869 Filed 9–24–14; 8:45 am]
mstockstill on DSK4VPTVN1PROD with NOTICES
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
VerDate Sep<11>2014
17:25 Sep 24, 2014
Jkt 232001
ACTION:
2,000
200
6000
200
200
100
20
200
1000
1000
200
200
40
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
SUMMARY:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
1
1
1
1
1
1
1
1
1
1
1
1
Average
burden per
response
(in hours)
45/60
15/60
10/60
30/60
15/60
45/60
30/60
15/60
30/60
30/60
20/60
20/60
30/60
Total annual
burden hour
1,500
50
1000
100
50
75
10
50
500
500
67
67
20
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
Miniature Serial Microtome for BlockFace Imaging
Description of Technology: A
microtome device is used in a variety of
microcopy techniques to remove very
thin (e.g., in the tens of nanometers
range) portions from the top of a sample
between successive images. This
technology discloses a design for a
microtome device that offers several
E:\FR\FM\25SEN1.SGM
25SEN1
mstockstill on DSK4VPTVN1PROD with NOTICES
57564
Federal Register / Vol. 79, No. 186 / Thursday, September 25, 2014 / Notices
unique features and advantages over
commercially available microtomes. A
prototype of the microtome has been
built and demonstrated to work with a
serial block-face scanning electron
microscopy in order to serially collect
ultrathin sections from plastic
embedded biological tissues,
specifically from brain tissues. This
microtome design allows for a sample to
be cut at a location removed from the
electron beam axis, thus reducing
interference from debris and allowing
imaging at a greater range of working
distances. This microtome device is
lightweight and easy to install utilizing
the built-in stage of existing
microscopes such that a sample’s
position and orientation can be
controlled along three-axes of rectilinear
translation and two axes of rotation.
This microtome design utilizes a
diamond blade coupled to both the base
plate and an actuator to control the
movement of the blade in a direction
perpendicular to the exposed surface of
the pedestal, while producing an output
signal that indicates the blade location
with respect to the base plate.
Advantageously, this allows for a stage
coupled pedestal to be moved
accurately from an imaging location on
the beam axis to a cutting location off
the beam axis.
Potential Commercial Applications:
Can be used in a variety of
microscopy techniques:
• Scanning electron microscopy.
• light-based (optical, fluorescence)
microscopy.
• cathodoluminescence microscopy.
Can be used to study any of various
types of sample materials:
• tissue microscopy.
• brain research.
• tissue sectioning.
• imaging.
Competitive Advantages:
• Is compatible with multiple
microscopy systems.
• incorporates a feedback sensor to
monitor and optimize cutting
thickness/forces.
• can cut reproducible sections as thin
as 25 nanometers.
• performs cutting off-axis to prevent
contamination.
• mounts rapidly onto an existing SEM
stage and does not require a custom
vacuum chamber door.
• uses the full range of an existing SEM
stage for positioning samples.
• incorporates a stage translation that is
rectilinear.
• utilizes a pivot flexure bearing for
frictionless rotation during cutting.
• cleans knife edge after each cut.
Development Stage:
VerDate Sep<11>2014
17:25 Sep 24, 2014
Jkt 232001
• In vitro data available.
• Prototype.
Inventor: Kevin Briggman (NINDS).
Intellectual Property: HHS Reference
No. E–121–2014/0—US Provisional
Application No. 61/991,929 filed 12
May 2014.
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Neurological
Disorders and Stroke is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize the microtome device.
For collaboration opportunities, please
contact Melissa Maderia, Ph.D., M.B.A.
at maderiam@mail.nih.gov or 240–276–
5533.
Chimeric Receptors Targeting CD–19
Description of Technology: Available
for licensing are compositions and
methods for targeting and destroying
CD19-expressing cancers, especially Bcell malignancies such as lymphomas
and leukemias.
The antibody used in this technology
is called anti-CD19. CD19 antibodies
have been used to treat people with
lymphoma and Leukemia. This
technology has changed the anti-CD19
antibody so that instead of floating free
in the blood, its CD19-binding domain
is now joined to a T cell. When an
antibody is joined to a T cell in this way
it is called a chimeric receptor. Once
localized at a CD19-expressing cancer
cell, the T-cell portion of the chimeric
receptor stimulates an immune response
to destroy the cancer cell.
Potential Commercial Applications:
Therapeutic agents to treat or prevent
CD19-expressing cancers, including Bcell malignancies.
Competitive Advantages: Reduced
toxicity and immunogenicity in humans
of previous anti-CD19 chimeric
receptors containing mouse sequences.
Development Stage:
• Early-stage.
• In vitro data available.
Inventor: James Kochenderfer (NCI).
Intellectual Property: HHS Reference
No. E–042–2014/0—US Provisional
Application No. 62/006,313 filed 02
June 2014.
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560; mccuepat@
od.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize chimeric antigen
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
receptors targeting CD19. For
collaboration opportunities, please
contact John D. Hewes, Ph.D. at hewesj@
mail.nih.gov.
Use of Small Molecules To Treat
PARP1-Deficient Cancers
Description of Technology: Scientists
at the National Human Genome
Research Institute and the National
Center for Advancing Translational
Sciences have identified a class of small
molecules synergistically working with
known Poly (ADP-ribose) polymerase 1
(PARP–1)-inhibitors. These new small
molecules can each effectively kill
specific PARP–1 defective tumors cells
and show synergy with known PARP1
inhibitors (PARP–1i) in killing tumor
cells.
PARP1, a highly conserved DNA
binding protein, is essential for
repairing DNA damage and plays
important roles in multiple DNA
damage response pathways. Many
cancer therapies utilize DNA-damaging
agents to kill tumor cells, which often
triggers DNA repair (e.g., by activating
PARP1 pathways). Additionally, a
variety of cancer types may also carry
PARP1 mutation(s), such as glioma,
breast cancer, and prostate cancer. Such
mutations render the cancer cells
resistant to these therapies. The key
feature of these PARP–1i sensitizing
molecules can be applied either as
useful sensitizers in combinatorial
treatment to increase the efficacy of
DNA-damaging agents in cancer
therapy, or selective targeting of cancer
cells with specific DNA PARP–1
defects; thereby allowing for the
development of new therapies.
Potential Commercial Applications:
Therapies for cancers associated with
PARP–1 defects.
Competitive Advantages:
• Utilizes proven small-molecule
technology.
• Specificity of mode of action may
reduce potential side-effects.
• Novel mode of action may limit
market competition.
• Combinatorial therapies of cancers
with PARP–1 inhibitors.
Development Stage: In vitro data
available.
Inventors: Kyungjae Myung (NHGRI),
et al.
Publications:
1. Papeo G, et al. PARP inhibitors in
cancer therapy: an update. Expert Opin
Ther Pat. 2013 Apr;23(4):503–14. [PMID
23379721].
2. Chiarugi A. A snapshot of
chemoresistance to PARP inhibitors.
Trends Pharmacol Sci. 2012
Jan;33(1):42–8. [PMID 22055391].
E:\FR\FM\25SEN1.SGM
25SEN1
Federal Register / Vol. 79, No. 186 / Thursday, September 25, 2014 / Notices
3. Yu H, et al. Association between
PARP–1 V762A polymorphism and
cancer susceptibility: a meta-analysis.
Genet Epidemiol. 2012 Jan;36(1):56–65.
[PMID 22127734].
Intellectual Property:
• HHS Reference No. E–039–2014/0—
U.S. Patent Application No. 61/
930,291 filed 22 Jan 2014.
• HHS Reference No. E–039–2014/1—
U.S. Patent Application No. 61/
988,502 filed 05 May 2014.
Licensing Contact: Eggerton
Campbell, Ph.D.; 301–435–5282;
eggerton.campbell@nih.gov.
Collaborative Research Opportunity:
The National Human Genome Research
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize small molecules to treat
PARP1-deficient cancer. For
collaboration opportunities, please
contact Anna Solowiej, Ph.D., J.D. at
solowieja@mail.nih.gov.
Dated: September 22, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–22763 Filed 9–24–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Healthy
Menopause.
Date: October 31, 2014.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2C212, 7201
VerDate Sep<11>2014
17:25 Sep 24, 2014
Jkt 232001
Wisconsin Avenue, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Isis S. Mikhail, MPH,
DRPH, National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Suite
2C212, Bethesda, MD 20892, 301–402–7702,
MIKHAILI@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS).
Dated: September 19, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–22762 Filed 9–24–14; 8:45 am]
BILLING CODE 4140–01–P
57565
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of This Information
Collection
DEPARTMENT OF HOMELAND
SECURITY
United States Immigration and
Customs Enforcement
Agency Information Collection
Activities: Extension, With Changes, of
an Existing Information Collection;
Comment Request
60-Day Notice of Information
collection for review; Form No. I–901;
Fee Remittance for Certain F, J and M
Non-immigrants; OMB Control No.
1653–0034.
ACTION:
The Department of Homeland
Security, U.S. Immigration and Customs
Enforcement (USICE), is submitting the
following information collection request
for review and clearance in accordance
with the Paperwork Reduction Act of
1995. The information collection is
published in the Federal Register to
obtain comments from the public and
affected agencies. Comments are
encouraged and will be accepted for
sixty day until November 24, 2014.
Written comments and suggestions
regarding items contained in this notice
and especially with regard to the
estimated public burden and associated
response time should be directed to the
Office of Chief Information Office,
Forms Management Office, U.S.
Immigrations and Customs
Enforcement, 801 I Street NW., Mailstop
5800, Washington, DC 20536–5800.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information should address one or more
of the following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agencies estimate of the burden of the
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
(1) Type of Information Collection:
Extension, with changes, of a currently
approved information collection.
(2) Title of the Form/Collection: Fee
Remittance for Certain F, J and M Nonimmigrants.
(3) Agency form number, if any, and
the applicable component of the
Department of Homeland Security
sponsoring the collection: Form I–901,
U.S. Immigration and Customs
Enforcement.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Individuals or
households. Public Law 104–208,
Subtitle D, Section 641 directs the
Attorney General, in consultation with
the Secretary of State and the Secretary
of Education, to develop and conduct a
program to collect information on
nonimmigrant foreign students and
exchange visitors from approved
institutions of higher education, as
defined in section 101(a) of the Higher
Education Act of 1965, as amended or
in a program of study at any other DHS
approved academic or language-training
institution, to include approved private
elementary and secondary schools and
public secondary schools, and from
approved exchange visitor program
sponsors designated by the Department
of State (DOS). It also authorized a fee,
not to exceed $200, to be collected from
these students and exchange visitors to
support this information collection
program. DHS has implemented the
Student and Exchange Visitor
Information System (SEVIS) to carry out
this statutory requirement.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: 805,786 responses at 19
minutes (.32 hours) per response.
(6) An estimate of the total public
burden (in hours) associated with the
collection: 257,852 annual burden
hours.
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 79, Number 186 (Thursday, September 25, 2014)]
[Notices]
[Pages 57563-57565]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-22763]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Miniature Serial Microtome for Block-Face Imaging
Description of Technology: A microtome device is used in a variety
of microcopy techniques to remove very thin (e.g., in the tens of
nanometers range) portions from the top of a sample between successive
images. This technology discloses a design for a microtome device that
offers several
[[Page 57564]]
unique features and advantages over commercially available microtomes.
A prototype of the microtome has been built and demonstrated to work
with a serial block-face scanning electron microscopy in order to
serially collect ultrathin sections from plastic embedded biological
tissues, specifically from brain tissues. This microtome design allows
for a sample to be cut at a location removed from the electron beam
axis, thus reducing interference from debris and allowing imaging at a
greater range of working distances. This microtome device is
lightweight and easy to install utilizing the built-in stage of
existing microscopes such that a sample's position and orientation can
be controlled along three-axes of rectilinear translation and two axes
of rotation. This microtome design utilizes a diamond blade coupled to
both the base plate and an actuator to control the movement of the
blade in a direction perpendicular to the exposed surface of the
pedestal, while producing an output signal that indicates the blade
location with respect to the base plate. Advantageously, this allows
for a stage coupled pedestal to be moved accurately from an imaging
location on the beam axis to a cutting location off the beam axis.
Potential Commercial Applications:
Can be used in a variety of microscopy techniques:
Scanning electron microscopy.
light-based (optical, fluorescence) microscopy.
cathodoluminescence microscopy.
Can be used to study any of various types of sample materials:
tissue microscopy.
brain research.
tissue sectioning.
imaging.
Competitive Advantages:
Is compatible with multiple microscopy systems.
incorporates a feedback sensor to monitor and optimize cutting
thickness/forces.
can cut reproducible sections as thin as 25 nanometers.
performs cutting off-axis to prevent contamination.
mounts rapidly onto an existing SEM stage and does not require
a custom vacuum chamber door.
uses the full range of an existing SEM stage for positioning
samples.
incorporates a stage translation that is rectilinear.
utilizes a pivot flexure bearing for frictionless rotation
during cutting.
cleans knife edge after each cut.
Development Stage:
In vitro data available.
Prototype.
Inventor: Kevin Briggman (NINDS).
Intellectual Property: HHS Reference No. E-121-2014/0--US
Provisional Application No. 61/991,929 filed 12 May 2014.
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Neurological Disorders and Stroke is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate or commercialize the microtome device. For
collaboration opportunities, please contact Melissa Maderia, Ph.D.,
M.B.A. at maderiam@mail.nih.gov or 240-276-5533.
Chimeric Receptors Targeting CD-19
Description of Technology: Available for licensing are compositions
and methods for targeting and destroying CD19-expressing cancers,
especially B-cell malignancies such as lymphomas and leukemias.
The antibody used in this technology is called anti-CD19. CD19
antibodies have been used to treat people with lymphoma and Leukemia.
This technology has changed the anti-CD19 antibody so that instead of
floating free in the blood, its CD19-binding domain is now joined to a
T cell. When an antibody is joined to a T cell in this way it is called
a chimeric receptor. Once localized at a CD19-expressing cancer cell,
the T-cell portion of the chimeric receptor stimulates an immune
response to destroy the cancer cell.
Potential Commercial Applications: Therapeutic agents to treat or
prevent CD19-expressing cancers, including B-cell malignancies.
Competitive Advantages: Reduced toxicity and immunogenicity in
humans of previous anti-CD19 chimeric receptors containing mouse
sequences.
Development Stage:
Early-stage.
In vitro data available.
Inventor: James Kochenderfer (NCI).
Intellectual Property: HHS Reference No. E-042-2014/0--US
Provisional Application No. 62/006,313 filed 02 June 2014.
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
mccuepat@od.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
chimeric antigen receptors targeting CD19. For collaboration
opportunities, please contact John D. Hewes, Ph.D. at
hewesj@mail.nih.gov.
Use of Small Molecules To Treat PARP1-Deficient Cancers
Description of Technology: Scientists at the National Human Genome
Research Institute and the National Center for Advancing Translational
Sciences have identified a class of small molecules synergistically
working with known Poly (ADP-ribose) polymerase 1 (PARP-1)-inhibitors.
These new small molecules can each effectively kill specific PARP-1
defective tumors cells and show synergy with known PARP1 inhibitors
(PARP-1i) in killing tumor cells.
PARP1, a highly conserved DNA binding protein, is essential for
repairing DNA damage and plays important roles in multiple DNA damage
response pathways. Many cancer therapies utilize DNA-damaging agents to
kill tumor cells, which often triggers DNA repair (e.g., by activating
PARP1 pathways). Additionally, a variety of cancer types may also carry
PARP1 mutation(s), such as glioma, breast cancer, and prostate cancer.
Such mutations render the cancer cells resistant to these therapies.
The key feature of these PARP-1i sensitizing molecules can be applied
either as useful sensitizers in combinatorial treatment to increase the
efficacy of DNA-damaging agents in cancer therapy, or selective
targeting of cancer cells with specific DNA PARP-1 defects; thereby
allowing for the development of new therapies.
Potential Commercial Applications: Therapies for cancers associated
with PARP-1 defects.
Competitive Advantages:
Utilizes proven small-molecule technology.
Specificity of mode of action may reduce potential side-
effects.
Novel mode of action may limit market competition.
Combinatorial therapies of cancers with PARP-1 inhibitors.
Development Stage: In vitro data available.
Inventors: Kyungjae Myung (NHGRI), et al.
Publications:
1. Papeo G, et al. PARP inhibitors in cancer therapy: an update.
Expert Opin Ther Pat. 2013 Apr;23(4):503-14. [PMID 23379721].
2. Chiarugi A. A snapshot of chemoresistance to PARP inhibitors.
Trends Pharmacol Sci. 2012 Jan;33(1):42-8. [PMID 22055391].
[[Page 57565]]
3. Yu H, et al. Association between PARP-1 V762A polymorphism and
cancer susceptibility: a meta-analysis. Genet Epidemiol. 2012
Jan;36(1):56-65. [PMID 22127734].
Intellectual Property:
HHS Reference No. E-039-2014/0--U.S. Patent Application No.
61/930,291 filed 22 Jan 2014.
HHS Reference No. E-039-2014/1--U.S. Patent Application No.
61/988,502 filed 05 May 2014.
Licensing Contact: Eggerton Campbell, Ph.D.; 301-435-5282;
eggerton.campbell@nih.gov.
Collaborative Research Opportunity: The National Human Genome
Research Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize small molecules to treat PARP1-deficient
cancer. For collaboration opportunities, please contact Anna Solowiej,
Ph.D., J.D. at solowieja@mail.nih.gov.
Dated: September 22, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-22763 Filed 9-24-14; 8:45 am]
BILLING CODE 4140-01-P
